By Emily Hayes, LabPulse.com editor in chief

September 30, 2019 -- Blood-based next-generation sequencing for identifying ALK genetic mutations and guiding drug treatment accordingly was validated in Roche's BFAST study of non-small cell lung cancer (NSCLC), researchers reported in a September 30 presentation at the European Society for Medical Oncology (ESMO) Congress.

In the phase II/III Blood First Assay Screening Trial (BFAST), 2,219 patients with previously untreated NSCLC were screened for genetic mutations; 5.4% (119) had a rearrangement of the ALK gene. That's the proportion that would be expected with traditional tissue biopsies, reported University of Michigan oncologist Dr. Shirish Gadgeel and colleagues at the meeting, which is being held in Barcelona, Spain.

The FoundationOne Liquid test was used to direct patients to treatment with the Roche's ALK inhibitor alectinib (Alecensa). In the year after treatment, the confirmed objective response rate was 87.4% and the 12-month duration of response was 75.9%. The 12-month progression-free survival rate was 78.4%, with the median not reached.

The data show that liquid biopsy can be used instead of tissue sample biopsy to identify relevant mutations for an increasing number of patients with lung cancer, commented Alberto Bardelli, PhD, a professor in the oncology department at the University of Turin in Italy, in a statement from ESMO. While the cost of liquid biopsy is high, this is likely to come down, allowing wider use, he added.

The ALK data represent the first cohort reported in BFAST, which is a multiarm study of Roche's blood-based cancer screening strategy for guiding treatment with cancer drugs. The trial is enrolling a total of 580 treatment-naive NSCLC patients. In addition to alectinib, BFAST investigators are studying blood testing as a means of guiding treatment with atezolizumab (Tecentriq), a programmed cell death ligand 1 (PD-L1) inhibitor, and entrectinib (Rozlytrek), which is used in ROS1-positive NSCLC and NTRK fusion-positive solid tumors.

BFAST is the first prospective trial to use blood-based next-generation sequencing as the only test for identifying and assigning NSCLC patients to targeted therapy based on mutations, with no need for tissue biopsy, Roche noted in a statement.

Blood test helps gauge lung cancer risk in heavy smokers
Pairing a microRNA blood test with low-dose computed tomography scans helps assess risk for lung cancer and guide screening efforts, according to an Italian...
Blood biomarkers improve early detection of lung cancer
The combination of a lung cancer biomarker blood test and imaging-based screening helped improve the early detection of lung cancer in an ongoing national...
OncoCyte set to buy Razor, reveals plans for lung cancer tests
OncoCyte this week announced plans to acquire Razor Genomics and disclosed that it's aiming for a first-quarter 2020 launch of the Razor predictive test...
Thermo Fisher flags data for tumor mutation test
Thermo Fisher Scientific will showcase new research involving its Oncomine tumor mutation load assay and how it relates to cancer immunotherapy response...

Copyright © 2019 LabPulse.com

Last Updated eh 10/1/2019 3:39:34 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email